We are live on ! Find out more
PTHS

Pelthos Therapeutics
PTHS

17 hedge funds and large institutions have $19.2M invested in Pelthos Therapeutics in 2026 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 2

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

13% more funds holding

Funds holding: 15 → 17 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1.95% less ownership

Funds ownership: 29.14% → 27.19% (-1.9%)

31% less capital invested

Capital invested by funds: $27.9M → $19.2M (-$8.71M)

Holders
17
Holders Change
+2
Holders Change %
+13.33%
% of All Funds
0.21%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
5
Increased
8
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
M
Murchinson
Ontario, Canada
+$162K
2
CF
Cantor Fitzgerald
New York
+$153K
3
PFCS
Pale Fire Capital SE
Czech Republic
+$114K
4
DMKJ
David M. Knott Jr
+$42.5K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$39.5K

Top Sellers

Rank Fund Capital Flow
1
JGC
J. Goldman & Co
New York
-$654K
2
Millennium Management
Millennium Management
New York
-$343K
3
DP
Diadema Partners
New Jersey
-$5.38K
4
Bank of America
Bank of America
North Carolina
-$372
Name Holding Trade Value Shares
Change 		Change in
Stake
M
1
Murchinson
Ontario, Canada
$6.23M +$162K +6,835 +2%
IC
2
Ikarian Capital
Texas
$5.39M +$19.9K +840 +0.3%
VCM
3
Vanguard Capital Management
Pennsylvania
$1.96M +$2.21M +93,093 New
BFM
4
Boothbay Fund Management
New York
$1.72M +$27.9K +1,178 +1%
JGC
5
J. Goldman & Co
New York
$1.06M -$654K -27,591 -35%
CF
6
Cantor Fitzgerald
New York
$870K +$153K +6,433 +18%
DP
7
Diadema Partners
New Jersey
$520K -$5.38K -227 -0.9%
DMKJ
8
David M. Knott Jr
$443K +$42.5K +1,792 +9%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$321K +$39.5K +1,665 +12%
PFCS
10
Pale Fire Capital SE
Czech Republic
$271K +$114K +4,819 +59%
VFT
11
Vanguard Fiduciary Trust
Pennsylvania
$206K +$233K +9,817 New
PAP
12
Persistent Asset Partners
Hong Kong
$126K – – –
SPIA
13
Steward Partners Investment Advisory
New York
$40.1K – – –
UBS Group
14
UBS Group
Switzerland
$16.1K +$7.83K +330 +76%
FFA
15
Farther Finance Advisors
California
$852 +$949 +40 New
AP
16
Aspect Partners
Virginia
$336 +$379 +16 New
Citigroup
17
Citigroup
New York
$21 +$24 +1 New
Millennium Management
18
Millennium Management
New York
– -$343K -11,057 Closed
Bank of America
19
Bank of America
North Carolina
– -$372 -12 Closed

PTHS Hedge Fund Activity: Q1 2026 in Review

17 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Pelthos Therapeutics (PTHS) for Q1 2026, worth a combined $19.2M — down 31% from $27.9M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new PTHS positions and 2 closed out — a net gain of 3 holders — while 8 added to existing stakes and 2 trimmed.

The largest buyer was Murchinson, adding an estimated $162K. The largest seller was J. Goldman & Co, cutting an estimated $654K.

  • 17 institutional investors held Pelthos Therapeutics (PTHS) as of Q1 2026, up from 15 in Q4 2025.
  • Funds reported $19.2M of Pelthos Therapeutics stock for Q1 2026, down 31% quarter-over-quarter.
  • 5 funds opened new Pelthos Therapeutics positions in Q1 2026 and 2 closed out, a net change of +3 holders.
  • The largest Pelthos Therapeutics buyer in Q1 2026 was Murchinson, an estimated $162K added.
  • The largest Pelthos Therapeutics seller in Q1 2026 was J. Goldman & Co, an estimated $654K sold.

Based on aggregated 13F filings for Q1 2026.